Table 1.
Pharmacy standardized patient screening form.
Table 2.
Algorithm to assess the need for suspect products to undergo laboratory analysis.
Figure 1.
Flow diagram of Phase I and II Results.
Table 3.
Proportion of concurrent use of NHP and prescription medication by pharmacy.
Table 4.
Proportion with adverse events for those concurrently taking NHP and prescription medication (MED) by pharmacy.